ProfileGDS5678 / 1452789_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 88% 87% 89% 88% 83% 79% 83% 81% 90% 93% 90% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1704490
GSM967853U87-EV human glioblastoma xenograft - Control 26.9678188
GSM967854U87-EV human glioblastoma xenograft - Control 36.7025587
GSM967855U87-EV human glioblastoma xenograft - Control 47.1169589
GSM967856U87-EV human glioblastoma xenograft - Control 56.8799388
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9350583
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3655579
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0574183
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8159181
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2756990
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.798993
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2367890
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.4540891
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3443691